Countable Labs presented a PCR platform aimed at single-molecule quantification, targeting two persistent challenges in molecular measurement: rare-event sensitivity and run-to-run reproducibility. The company’s approach is positioned to overcome limitations of statistical inference methods that can introduce ambiguity for low-frequency targets such as circulating tumor DNA, minimal residual disease, and trace impurities in gene and cell therapy vectors. In the spotlight discussion, CEO Giovanna Prout emphasized that many PCR approaches deliver estimates rather than direct molecule counts, and that digital PCR can impose input constraints to improve statistics. Countable’s platform is positioned to enable more confident thresholding and cross-lab comparability. For biotech operations, the platform’s promise centers on measurement rigor—an area that becomes more critical as manufacturing and clinical trials increasingly depend on single-molecule-level decisions.